title: Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index.
abstract: BACKGROUND
  Hyperandrogenemia is one of the major diagnostic features for the diagnosis of polycystic ovary syndrome (PCOS). The aim of this study was to estimate the prevalence and the characteristics of hyperandrogenemia in women with PCOS and to investigate the association of clinical and biochemical characteristics with body mass index (BMI) according to the presence of hyperandrogenemia.
  
  
  METHODS
  We studied 266 women diagnosed with PCOS. Hyperandrogenemia was defined by testosterone (T) and/or free testosterone (FT) and/or ∆4 androstenedione (Δ4-A) higher than 75% of the upper limits of each hormone. Patients were stratified in two groups according to a BMI threshold of 25 kg/m2.
  
  
  RESULTS
  Hyperandrogenemia was present in 78.2% of the patients. Elevated levels of T were found in 58.4%, while elevated levels of FT and Δ4-A were found in 42.5% and 34.1% of patients. In normal weight women (BMI≤25 kg/m2) with hyperandrogenemia lower values of hip circumference and HOMA-IR and increased levels of T, FT, Δ4-A, 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEAS), white blood cells (WBC) and neutrophils were observed compared to women without hyperandrogenemia. Also, in overweight women higher levels of T, FT, Δ4-A, 17-OHP, DHEAS and cortisol were measured, while lower thyroid-stimulating hormone (TSH) levels were comparable to women without hyperandrogenemia.
  
  
  CONCLUSIONS
  This study showed high prevalence of hyperandrogenemia in PCOS women. Women with BMI≤25 kg/m2 have significant differences in androgens, WBC, neutrophils and HOMA-IR and women with BMI≥25 kg/m2 in androgens, TSH and cortisol according to the presence or not of hyperandrogenemia.
authors.forename: Eleni
authors.initials: E
authors.lastname: Alexiou
authors.forename: Erifili
authors.initials: E
authors.lastname: Hatziagelaki
authors.forename: Vasilios
authors.initials: V
authors.lastname: Pergialiotis
authors.forename: Charalampos
authors.initials: C
authors.lastname: Chrelias
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kassanos
authors.forename: Charalampos
authors.initials: C
authors.lastname: Siristatidis
authors.forename: Giannoula
authors.initials: G
authors.lastname: Kyrkou
authors.forename: Maria
authors.initials: M
authors.lastname: Kreatsa
authors.forename: Eftihios
authors.initials: E
authors.lastname: Trakakis
mesh_terms: D000328:Adult; D000728:Androgens / Q000097:blood*; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000453:epidemiology* / Q000473:pathology*; D015995:Prevalence; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D000728:Androgens